newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase